Veos Pharmaceuticals develops and commercializes biotechnology solutions for human health, agriculture, and environmental systems, leveraging scientifically rigorous platforms manufactured in Europe and distributed globally.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many sectors—including human health, agriculture, and environmental management—lack accessible, scientifically validated biotechnology products that can be reliably manufactured at scale and delivered worldwide. This gap limits the ability of clinicians, growers, and water treatment providers to adopt advanced solutions that improve health outcomes, crop performance, and ecosystem sustainability.
Solution
Veos Pharmaceuticals addresses this gap by developing and commercializing biotechnology solutions built on rigorously validated scientific platforms. The company manufactures its products in Europe to ensure high quality and regulatory compliance, then distributes them globally through partnerships with clinicians, growers, distributors, and research institutions. Recent launches include BioPropello™, a crop‑performance enhancer entering the Japanese market, and ThymoTropin™, a nutraceutical aimed at preserving muscle health during weight loss and aging. By leveraging a portfolio of patented technologies across human health, agri‑biotech, water treatment, and nutraceuticals, Veos creates scalable, science‑led products that can be integrated into existing clinical, agricultural, and environmental workflows.
Target Audience
Primary customers include healthcare providers and nutraceutical distributors, agricultural growers and agribusiness firms, and water‑treatment operators seeking scientifically validated biotech solutions.
Features
- European‑based manufacturing facilities that meet stringent quality and regulatory standards
- Portfolio of over 76 worldwide patents covering human health, agriculture, water treatment, and nutraceutical applications
- Multi‑sector platform approach enabling cross‑application of core biotechnologies
- Partner‑centric commercialization model with clinicians, growers, distributors, and research institutions
- Products designed for global distribution, exemplified by BioPropello™ launch in Japan and ThymoTropin™ for muscle health
- Emphasis on scientific rigor throughout development, from pre‑clinical research to market rollout